{"nctId":"NCT00415597","briefTitle":"Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain","startDateStruct":{"date":"2006-12"},"conditions":["Pain"],"count":467,"armGroups":[{"label":"ALO-01","type":"EXPERIMENTAL","interventionNames":["Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)"]}],"interventions":[{"name":"ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)","otherNames":["Embeda"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject 18-70 years of age\n* Subject agrees to refrain from taking any opioid medications other than study medication during study period.\n* History of chronic moderate to severe pain caused by a nonmalignant condition for at least 3 months prior to baseline\n\nExclusion Criteria:\n\n* Subject has a documented history of allergic reaction or clinically significant intolerance to morphine or other opioids, such that treatment with morphine is contraindicated.\n* Subject is pregnant or breast-feeding.\n* Subject is receiving chemotherapy, or has an active malignancy of any type or has been diagnosed with cancer within the past three years (excluding squamous or basal cell carcinoma of the skin).\n* Subject has a documented history of drug abuse/dependence/misuse or narcotic analgesic abuse/dependence/misuse within five years prior to the Baseline Visit.\n* Subject has a Body Mass Index (BMI)\\>45kg/m2.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subjects With Treatment Emergent Adverse Events","description":"Number of subjects with adverse events (any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the product whether or not related to the product).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"378","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline to 12 Weeks in Brief Pain Inventory Score (BPI) of Average Pain","description":"Percent change in pain intensity scale. Average pain intensity over last 24 hours rated at each visit from 0=no pain to 10=worst pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.3","spread":"37.44"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline to 52 Weeks in Brief Pain Inventory Score (BPI) of Average Pain","description":"Percent change in pain intensity scale. Average pain intensity over last 24 hours rated at each visit from 0=no pain to 10=worst pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.5","spread":"39.28"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":465},"commonTop":["Constipation","Nausea","Headache","Vomiting","Somnolence"]}}}